MNPR Monopar Therapeutics

  1. Stocks
  2. Healthcare
  3. NASDAQ: MNPR

Price (delayed)

$0.65

Market cap

$11.35M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.61

Enterprise value

$4.08M

Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of ...

Highlights
The company's debt has shrunk by 100% YoY
The EPS has grown by 27% YoY and by 15% from the previous quarter
The equity has contracted by 45% YoY and by 15% from the previous quarter
Monopar Therapeutics's quick ratio has decreased by 3.7% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.monopartx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of MNPR
Market
Shares outstanding
17.45M
Market cap
$11.35M
Enterprise value
$4.08M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.73
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$8.4M
EBITDA
-$8.4M
Free cash flow
-$7.86M
Per share
EPS
-$0.61
Free cash flow per share
-$0.57
Book value per share
$0.38
Revenue per share
$0
TBVPS
$0.53
Balance sheet
Total assets
$7.35M
Total liabilities
$1.76M
Debt
$0
Equity
$5.59M
Working capital
$5.58M
Liquidity
Debt to equity
0
Current ratio
4.17
Quick ratio
4.13
Net debt/EBITDA
0.86
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-88.2%
Return on equity
-116%
Return on invested capital
-1,031.3%
Return on capital employed
-150.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MNPR stock price

How has the Monopar Therapeutics stock price performed over time
Intraday
0%
1 week
3.17%
1 month
1.56%
1 year
-32.3%
YTD
91.06%
QTD
-4.55%

Financial performance

How have Monopar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$8.83M
Net income
-$8.4M
Gross margin
N/A
Net margin
N/A
The net income has grown by 20% year-on-year and by 11% since the previous quarter
The operating income has grown by 16% YoY and by 10% from the previous quarter

Growth

What is Monopar Therapeutics's growth rate over time

Valuation

What is Monopar Therapeutics stock price valuation
P/E
N/A
P/B
1.73
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 27% YoY and by 15% from the previous quarter
MNPR's price to book (P/B) is 50% less than its 5-year quarterly average of 3.5 but 26% more than its last 4 quarters average of 1.4
The equity has contracted by 45% YoY and by 15% from the previous quarter

Efficiency

How efficient is Monopar Therapeutics business performance
Monopar Therapeutics's ROIC has plunged by 86% from the previous quarter
MNPR's return on equity is down by 49% year-on-year and by 2.4% since the previous quarter
The return on assets has declined by 31% year-on-year and by 2.3% since the previous quarter

Dividends

What is MNPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MNPR.

Financial health

How did Monopar Therapeutics financials performed over time
The total liabilities has declined by 44% year-on-year and by 11% since the previous quarter
The total assets has declined by 44% year-on-year and by 15% since the previous quarter
The company's debt is 100% lower than its equity
The company's debt has shrunk by 100% YoY
The equity has contracted by 45% YoY and by 15% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.